MaltSci 麦伴科研

Appearance

Popular Reports / hepatology

This report is written by MaltSci based on the latest literature and research findings

How does liver cirrhosis develop and progress? ​

Abstract ​

Liver cirrhosis is a significant global health concern resulting from chronic liver injury, characterized by the replacement of healthy hepatic tissue with fibrotic scar tissue, leading to impaired liver function. The rise in prevalence of cirrhosis is closely linked to increasing rates of chronic liver diseases, including viral hepatitis, alcoholic liver disease, and non-alcoholic fatty liver disease (NAFLD). Understanding the intricate mechanisms that govern the development and progression of liver cirrhosis is crucial for effective management and therapeutic strategies. This review systematically explores the pathophysiology of liver cirrhosis, detailing the mechanisms of liver injury, the roles of inflammation and fibrosis, and the stages of cirrhosis from compensated to decompensated states. Key risk factors and comorbidities are highlighted, with a focus on their contributions to disease progression. Current diagnostic approaches, including clinical assessments, imaging techniques, and biomarkers, are reviewed to emphasize their importance in early detection and monitoring. Management strategies encompass lifestyle modifications, pharmacological treatments, and emerging therapeutic interventions, including liver transplantation. By synthesizing current research findings, this report aims to provide a comprehensive overview of liver cirrhosis, ultimately contributing to the enhancement of therapeutic strategies and patient outcomes in this challenging area of medicine.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Pathophysiology of Liver Cirrhosis
    • 2.1 Mechanisms of Liver Injury
    • 2.2 Role of Inflammation and Fibrosis
  • 3 Stages of Liver Cirrhosis
    • 3.1 Compensated Cirrhosis
    • 3.2 Decompensated Cirrhosis
  • 4 Risk Factors and Comorbidities
    • 4.1 Alcoholic Liver Disease
    • 4.2 Non-Alcoholic Fatty Liver Disease (NAFLD)
    • 4.3 Viral Hepatitis
  • 5 Diagnostic Approaches
    • 5.1 Clinical Assessment
    • 5.2 Imaging Techniques
    • 5.3 Biomarkers
  • 6 Management and Treatment Strategies
    • 6.1 Lifestyle Modifications
    • 6.2 Pharmacological Treatments
    • 6.3 Liver Transplantation
  • 7 Conclusion

1 Introduction ​

Liver cirrhosis represents the culmination of chronic liver injury and is characterized by the replacement of healthy hepatic tissue with fibrotic scar tissue, leading to significant impairment of liver function. The disease is a major global health concern, contributing to substantial morbidity and mortality, with the prevalence of cirrhosis rising in tandem with the increasing incidence of chronic liver diseases, including viral hepatitis, alcoholic liver disease, and non-alcoholic fatty liver disease (NAFLD) [1][2]. Understanding the intricate mechanisms that govern the development and progression of liver cirrhosis is paramount for the establishment of effective prevention and management strategies.

The significance of studying liver cirrhosis lies not only in its impact on individual health but also in its broader implications for public health systems. Chronic liver disease can lead to various complications, including hepatocellular carcinoma, portal hypertension, and liver failure, necessitating liver transplantation as the only definitive treatment option at advanced stages [3]. Furthermore, as liver cirrhosis progresses, the regenerative capacity of the liver becomes overwhelmed, leading to a vicious cycle of fibrosis and functional decline [1]. This underscores the urgent need for a deeper understanding of the underlying pathophysiological mechanisms, which may unveil novel therapeutic targets and intervention strategies [4].

Research on liver cirrhosis has evolved significantly over the past few decades, with advancements in molecular biology and immunology shedding light on the complex interplay of factors that contribute to its pathogenesis. Chronic inflammation, oxidative stress, and dysregulation of the gut-liver axis have emerged as critical components in the development of liver cirrhosis [2][5]. Notably, the role of the gut microbiota in liver health has gained prominence, as dysbiosis has been linked to the progression of liver diseases [6][7]. Recent studies have also highlighted the importance of the immune microenvironment and the involvement of various cytokines and immune cells in the fibrogenic process [5][8].

This review will systematically explore the multifaceted mechanisms underlying the development and progression of liver cirrhosis, structured as follows:

  1. Pathophysiology of Liver Cirrhosis: We will delve into the mechanisms of liver injury and the roles of inflammation and fibrosis in cirrhosis progression. This section will examine how chronic insults to the liver lead to cellular and molecular alterations that drive fibrosis [1][3].

  2. Stages of Liver Cirrhosis: A discussion on compensated and decompensated cirrhosis will elucidate the clinical manifestations and prognostic implications associated with each stage [2].

  3. Risk Factors and Comorbidities: This section will highlight the various etiological factors contributing to liver cirrhosis, including alcoholic liver disease, NAFLD, and viral hepatitis, and their interactions with comorbid conditions [9][10].

  4. Diagnostic Approaches: We will review current diagnostic strategies, including clinical assessments, imaging techniques, and biomarkers, which are critical for early detection and monitoring of cirrhosis [1][8].

  5. Management and Treatment Strategies: This section will discuss lifestyle modifications, pharmacological treatments, and emerging therapeutic interventions, including liver transplantation, aimed at managing liver cirrhosis [1][3].

  6. Conclusion: We will summarize the key findings and highlight the need for interdisciplinary research to bridge the gap between pathophysiology and clinical practice in the management of liver cirrhosis [1][3].

By synthesizing current research findings, this report aims to provide a comprehensive overview of the development and progression of liver cirrhosis, ultimately contributing to the enhancement of therapeutic strategies and patient outcomes in this challenging area of medicine.

2 Pathophysiology of Liver Cirrhosis ​

2.1 Mechanisms of Liver Injury ​

Liver cirrhosis is a complex and progressive condition that results from sustained liver injury and chronic inflammation, ultimately leading to extensive fibrosis, disrupted liver architecture, and impaired liver function. The pathophysiology of liver cirrhosis involves multiple interrelated mechanisms, including persistent inflammation, immune dysfunction, and cellular changes.

Chronic liver diseases, such as chronic hepatitis B and C, alcoholic liver disease, and non-alcoholic fatty liver disease, are primary contributors to the development of cirrhosis. These conditions induce continuous damage to liver tissues, leading to necrosis and the formation of fibrous tissue as part of the liver's repair response. Over time, this process results in an accumulation of scar tissue, which disrupts the normal hepatic architecture and impairs liver function (Zihe Dong et al., 2024; Rabab Abdel-Majeed Hegazy, 2025).

One of the key mechanisms driving liver injury is the activation of hepatic stellate cells (HSCs). These cells are normally quiescent but become activated in response to pro-fibrotic signals, such as transforming growth factor-beta (TGF-β) and inflammatory cytokines. Activated HSCs transform into myofibroblasts, which produce excessive amounts of extracellular matrix components, including collagen, leading to fibrosis (Partha Pratim Das and Subhash Medhi, 2023; Rabab Abdel-Majeed Hegazy, 2025).

The immune response plays a critical role in the progression of liver cirrhosis. Chronic inflammation triggers the release of various cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6), which contribute to hepatocyte necrosis and the activation of fibrogenic pathways. Additionally, inflammasomes, which are multi-protein complexes that regulate the immune response, have been implicated in the inflammatory processes associated with liver cirrhosis (Partha Pratim Das and Subhash Medhi, 2023).

Another significant aspect of liver cirrhosis is the disruption of the gut-liver axis. Dysbiosis, characterized by an imbalance in the gut microbiota, has been shown to influence liver pathology. Increased levels of certain bacterial populations can lead to bacterial translocation, where microbes enter the portal circulation and reach the liver, exacerbating inflammation and fibrosis (Roman Maslennikov et al., 2023; Zihe Dong et al., 2024).

As cirrhosis progresses, the liver's ability to maintain homeostasis is compromised, resulting in systemic complications, including portal hypertension, liver failure, and an increased risk of hepatocellular carcinoma (HCC). The fibrotic tissue alters blood flow within the liver, leading to increased vascular resistance and subsequent portal hypertension, which can cause further liver injury and complications (Rabab Abdel-Majeed Hegazy, 2025).

In conclusion, the development and progression of liver cirrhosis involve a multifaceted interplay of chronic liver injury, immune dysregulation, and changes in the hepatic microenvironment. Understanding these mechanisms is crucial for developing effective therapeutic strategies aimed at reversing or mitigating the progression of cirrhosis and its associated complications.

2.2 Role of Inflammation and Fibrosis ​

Liver cirrhosis is a complex and progressive condition resulting from chronic liver injury and inflammation. It represents the end stage of various chronic liver diseases, characterized by extensive fibrosis, disrupted liver architecture, and impaired liver function. The development of cirrhosis is fundamentally linked to the processes of inflammation and fibrosis, which are intricately intertwined.

Chronic liver injury, whether due to viral infections, alcohol abuse, or metabolic disorders, initiates a cascade of inflammatory responses. This inflammation is primarily mediated by various immune cells and cytokines. Inflammatory mediators, such as tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6), and interferon-gamma (IFN-γ), play significant roles in promoting liver cell necrosis and subsequent fibrosis [5]. The activation of hepatic stellate cells (HSCs) is a pivotal event in the fibrogenesis process. Under normal conditions, HSCs are quiescent, but upon liver injury, they become activated and transdifferentiate into myofibroblast-like cells, leading to excessive deposition of extracellular matrix components, particularly collagen [11].

The interaction between inflammatory cells and the extracellular matrix contributes to the pathological remodeling of liver tissue. Repeated cycles of hepatocyte injury and inflammation result in the accumulation of fibrous tissue, which disrupts normal liver architecture and function [12]. The formation of fibrous septa and regenerative nodules in the liver is a hallmark of cirrhosis, reflecting ongoing attempts at tissue repair amidst persistent injury [5].

Inflammation and fibrosis are not merely sequential events; they are part of a crosstalk network that exacerbates liver damage. For instance, activated HSCs produce pro-inflammatory cytokines that further recruit immune cells, perpetuating the inflammatory cycle [13]. Moreover, the disruption of the hepatic vascular structure due to fibrosis leads to portal hypertension, compounding the liver's dysfunction and contributing to the systemic effects associated with cirrhosis [5].

Research indicates that the immune microenvironment significantly influences the progression of liver cirrhosis. The balance between pro-inflammatory and anti-inflammatory signals is crucial. For example, while pro-inflammatory cytokines promote fibrosis, anti-inflammatory cytokines like IL-10 can mitigate the inflammatory response and potentially reduce fibrogenesis [5]. However, in the context of chronic liver diseases, this balance is often skewed towards a pro-inflammatory state, facilitating the transition from liver inflammation to fibrosis and ultimately to cirrhosis [8].

Furthermore, the pathophysiology of liver cirrhosis involves not only local factors within the liver but also systemic influences, including alterations in the gut-liver axis. Dysbiosis of the intestinal microbiome has been implicated in the progression of liver diseases, as it can exacerbate liver inflammation and fibrosis [6].

In conclusion, liver cirrhosis develops through a multifaceted interplay of chronic inflammation and fibrogenesis, characterized by the activation of HSCs, excessive collagen deposition, and alterations in the immune response. Understanding these mechanisms is crucial for developing targeted therapeutic strategies aimed at halting or reversing the progression of liver cirrhosis.

3 Stages of Liver Cirrhosis ​

3.1 Compensated Cirrhosis ​

Liver cirrhosis is a complex and progressive condition resulting from chronic liver injury and sustained inflammation, characterized by extensive fibrosis, disrupted liver architecture, and impaired function. The development of cirrhosis typically follows a sequence of pathological events that can be broadly categorized into stages, beginning with compensated cirrhosis.

Compensated cirrhosis is the initial stage of liver cirrhosis where the liver retains sufficient function to maintain normal metabolic activities despite the presence of significant fibrosis and structural alterations. In this stage, the liver's ability to regenerate and repair itself is still relatively intact, and patients may not exhibit overt clinical symptoms. However, the underlying pathophysiological processes are already at play, as chronic liver injury continues to stimulate inflammatory responses and the activation of hepatic stellate cells (HSCs). These cells, when activated, contribute to the deposition of extracellular matrix components, leading to fibrosis and the formation of regenerative nodules within the liver [13].

The transition from compensated to decompensated cirrhosis occurs when the liver can no longer compensate for the structural damage and functional impairment. This transition is often precipitated by acute events, such as infections, alcohol consumption, or the development of portal hypertension. Decompensated cirrhosis is characterized by the onset of complications such as ascites, variceal bleeding, hepatic encephalopathy, and, ultimately, hepatocellular carcinoma (HCC) [14].

The progression of liver cirrhosis involves a dysregulation of the balance between tissue regeneration and fibrosis. Chronic liver injury, often due to factors such as viral hepatitis or alcohol abuse, leads to persistent inflammation, which drives the fibrotic process. This inflammation is mediated by various cytokines and immune responses, including the activation of inflammasomes that contribute to the production of pro-inflammatory cytokines such as TNF-α, IL-1, and IL-6 [5]. These cytokines promote liver cell necrosis and further exacerbate the fibrotic response [15].

Compensated cirrhosis can remain stable for extended periods, but it is crucial to recognize that it is a precursor to more severe forms of liver disease. Early detection and management of the underlying causes of liver injury are essential to prevent the progression to decompensated cirrhosis. Current therapeutic strategies focus on addressing the etiological factors, such as antiviral therapies for viral hepatitis or lifestyle modifications for alcohol-related liver disease, to halt or reverse the progression of fibrosis [16].

In summary, compensated cirrhosis represents a critical stage in the progression of liver disease where the liver maintains its function despite significant structural damage. Understanding the mechanisms underlying the transition to decompensated cirrhosis is vital for developing effective therapeutic interventions aimed at improving patient outcomes and quality of life.

3.2 Decompensated Cirrhosis ​

Liver cirrhosis is a progressive condition resulting from chronic liver injury, characterized by extensive fibrosis, regeneration of nodules, and disruption of normal liver architecture. The progression of cirrhosis can be categorized into several stages, with decompensated cirrhosis representing a critical and advanced phase of the disease.

The development of liver cirrhosis typically begins with chronic liver damage due to various etiologies, such as viral hepatitis, excessive alcohol consumption, and metabolic disorders. Over time, this persistent injury leads to inflammation and the activation of hepatic stellate cells, which are crucial in the fibrogenesis process. The resulting fibrotic tissue replaces healthy liver cells, impairing liver function and blood flow, which may eventually lead to portal hypertension.

Decompensated cirrhosis is marked by the emergence of significant clinical complications, including ascites, variceal bleeding, hepatic encephalopathy, and infections, particularly spontaneous bacterial peritonitis. This stage indicates a transition from compensated cirrhosis, where patients may remain asymptomatic or exhibit mild symptoms, to a state where the liver can no longer maintain homeostasis, leading to acute-on-chronic liver failure (ACLF) and a markedly poor prognosis[17].

Several factors contribute to the transition from compensated to decompensated cirrhosis. These include portal hypertension, which serves as a primary risk factor for decompensation, and systemic inflammation, which is a critical driving force for organ failure. The interplay between these factors is complex; systemic inflammation can exacerbate liver dysfunction and further increase portal pressure, creating a vicious cycle that accelerates disease progression[18].

Clinical manifestations of decompensated cirrhosis arise from a combination of underlying pathophysiological changes. For instance, increased gut permeability and microbial translocation can lead to systemic inflammation, exacerbating liver injury and promoting decompensation[19]. Moreover, the presence of complications such as infection and bleeding often precipitates acute decompensation events, significantly impacting patient survival rates[20].

In summary, liver cirrhosis progresses through stages characterized by increasing liver damage and functional impairment. Decompensated cirrhosis represents a critical phase where patients face severe complications, necessitating urgent medical intervention. Understanding the mechanisms driving this progression is essential for developing effective therapeutic strategies aimed at modifying disease outcomes and improving patient survival.

4 Risk Factors and Comorbidities ​

4.1 Alcoholic Liver Disease ​

Liver cirrhosis is a significant global health issue characterized by the progressive replacement of normal hepatic tissue with fibrotic scar tissue, ultimately leading to impaired liver function. The development and progression of cirrhosis, particularly in the context of alcoholic liver disease (ALD), is influenced by a complex interplay of various factors.

Alcoholic liver disease is primarily driven by excessive alcohol consumption, which leads to a series of pathological changes in the liver. Chronic alcohol intake causes the accumulation of lipids within liver cells (steatosis), and with ongoing exposure, this condition can progress to inflammation (alcoholic hepatitis) and eventually to cirrhosis. The severity of liver damage is correlated with both the quantity and duration of alcohol consumption, alongside other factors such as sex, obesity, and genetic predispositions [21].

The pathogenesis of alcoholic cirrhosis involves several key mechanisms. Alcohol is metabolized in the liver, producing toxic metabolites that not only induce direct hepatotoxicity but also disrupt the intestinal microbiota. This disruption leads to increased intestinal permeability, allowing bacterial products to translocate into the portal circulation, which in turn triggers systemic inflammatory responses and contributes to immune dysfunction, a phenomenon termed cirrhosis-associated immune dysfunction (CAID) [22]. This immune dysfunction is characterized by an imbalance in pro-inflammatory and anti-inflammatory cytokines, with elevated levels of cytokines such as TNF-α, IL-1, and IL-6 playing a critical role in liver cell necrosis and fibrosis [5].

Moreover, the progression of liver cirrhosis is also influenced by genetic factors. Studies have identified specific genetic polymorphisms that are associated with an increased risk of developing significant alcohol-related liver disease. These genetic predispositions, combined with environmental factors, contribute to the heterogeneity observed in the progression of alcoholic liver disease among individuals [23].

In addition to these biological mechanisms, the clinical presentation of alcoholic cirrhosis can vary significantly. Patients with alcoholic hepatitis may experience rapid deterioration of liver function, characterized by jaundice and a high risk of mortality. The prognosis is significantly influenced by the patient's adherence to abstinence from alcohol, with ten-year survival rates being markedly higher in abstinent individuals compared to those who relapse [21].

In conclusion, the development and progression of liver cirrhosis in the context of alcoholic liver disease are multifactorial, involving chronic alcohol exposure, immune dysfunction, genetic susceptibility, and the presence of comorbid conditions. Effective management strategies focus on early intervention to halt progression, including abstinence from alcohol, tailored immunomodulatory therapies, and in severe cases, liver transplantation as a definitive treatment option [21][22].

4.2 Non-Alcoholic Fatty Liver Disease (NAFLD) ​

Liver cirrhosis is a progressive condition that can develop as a consequence of various underlying liver diseases, with non-alcoholic fatty liver disease (NAFLD) being one of the most prevalent causes globally. NAFLD encompasses a spectrum of liver abnormalities ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), which can further progress to fibrosis, cirrhosis, and ultimately hepatocellular carcinoma (HCC) [24][25].

The development of liver cirrhosis from NAFLD is a multifactorial process influenced by a combination of metabolic, inflammatory, and fibrogenic pathways. Key risk factors include obesity, insulin resistance, type 2 diabetes, dyslipidemia, and metabolic syndrome [26][27]. These factors contribute to an increase in free fatty acids in the liver, leading to lipotoxicity and oxidative stress, which trigger hepatocyte injury, inflammation, and ultimately fibrosis [28][29].

The progression from NAFLD to cirrhosis involves several critical mechanisms. Initially, lipid accumulation in hepatocytes leads to steatosis, which can be benign in the absence of inflammation. However, in susceptible individuals, this can progress to NASH, characterized by hepatocyte ballooning, inflammation, and necrosis [30]. The inflammatory response in NASH activates hepatic stellate cells (HSCs), which are pivotal in the fibrogenic process. Once activated, HSCs produce excess extracellular matrix components, resulting in fibrosis [31].

As fibrosis progresses, the architecture of the liver becomes distorted, leading to increased portal pressure and further liver damage. This process can be exacerbated by additional factors such as gut microbiota dysbiosis, which has been shown to influence liver inflammation and fibrosis through the gut-liver axis [6][26]. Additionally, comorbidities such as cardiovascular diseases, which are common in NAFLD patients, can further complicate the clinical picture and accelerate the progression to cirrhosis [32].

The understanding of the transition from NAFLD to cirrhosis highlights the importance of early intervention and management of risk factors. Therapeutic strategies focusing on weight loss, insulin sensitization, and the modulation of gut microbiota are currently being explored as potential means to halt or reverse the progression of liver disease [29][31]. Furthermore, ongoing research aims to elucidate the specific molecular pathways involved in fibrosis development, which could lead to the identification of novel therapeutic targets for preventing cirrhosis in patients with NAFLD [26][28].

In summary, liver cirrhosis develops as a result of complex interactions between metabolic disturbances, inflammatory responses, and fibrogenic processes, with NAFLD serving as a significant precursor in this pathological continuum. Understanding these mechanisms is crucial for developing effective prevention and treatment strategies.

4.3 Viral Hepatitis ​

Liver cirrhosis is a complex and progressive condition resulting from sustained liver injury and chronic inflammation, primarily associated with chronic infections such as hepatitis B virus (HBV) and hepatitis C virus (HCV). These viral infections are among the leading causes of liver cirrhosis globally, accounting for a significant proportion of liver disease-related morbidity and mortality.

The development of liver cirrhosis typically involves a multifaceted process characterized by repetitive cycles of liver injury, inflammation, and tissue repair. Chronic hepatitis B and C infections induce a state of persistent inflammation that leads to the activation of hepatic stellate cells (HSCs), which are crucial for fibrogenesis. These cells, upon activation, secrete fibrosis-related factors that contribute to excessive collagen deposition and the formation of fibrous scar tissue, ultimately resulting in the disruption of normal liver architecture and function [33].

The progression from chronic viral hepatitis to cirrhosis generally takes 10 to 20 years. During this time, intermediate hepatic inflammation contributes to an inflammation-necrosis-regeneration cycle that is pivotal in the pathogenesis of cirrhosis. The immune response, particularly the action of CD8(+) T cells and natural killer (NK) cells, plays a dual role by targeting infected hepatocytes and releasing pro-inflammatory cytokines, which further exacerbates liver damage [33].

In the context of HCV infection, it has been shown that various genes involved in apoptosis, cell structure, signal transduction, proliferation, and immune response are differentially regulated during the progression of fibrosis. As the disease advances from mild to severe stages, there is an observed increase in proliferative and cell growth-related gene expression, while immune responses are downregulated, indicating a systematic progression towards advanced fibrosis and cirrhosis [34].

Furthermore, the inflammatory status in cirrhosis varies depending on the underlying cause. For instance, HCV-induced cirrhosis is characterized by mechanisms that facilitate viral evasion of the immune system, including inhibition of interferon secretion and T cell-mediated cytotoxicity. In contrast, alcohol-induced cirrhosis is driven by the hepatotoxic effects of ethanol and increased intestinal permeability, which leads to a stronger pro-inflammatory response compared to HCV-related cirrhosis [35].

As cirrhosis progresses, the liver's ability to maintain homeostasis is severely compromised, leading to a state of immunological dysfunction. This dysfunction is characterized by the dysregulation of cytokine production, which plays a significant role in the development of cirrhosis [5]. Pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) are upregulated, contributing to liver cell necrosis and fibrosis [5].

In summary, the development and progression of liver cirrhosis are closely linked to chronic viral hepatitis infections, which induce a persistent inflammatory response, activate fibrogenic pathways, and ultimately lead to significant architectural and functional alterations in the liver. Understanding these mechanisms is crucial for developing targeted therapeutic strategies to halt or reverse the progression of cirrhosis.

5 Diagnostic Approaches ​

5.1 Clinical Assessment ​

Liver cirrhosis is a complex and progressive condition that results from sustained liver injury and chronic inflammation. It is characterized by extensive fibrosis, disrupted liver architecture, and impaired function, representing the end stage of many chronic liver diseases. The development of cirrhosis is typically associated with various factors, including chronic viral hepatitis (particularly hepatitis B and C), alcoholic liver disease, and non-alcoholic fatty liver disease. The clinical course of cirrhosis can last several years, and while traditionally viewed as irreversible, emerging evidence suggests that targeted interventions may modify disease progression, offering new hope for patients [3].

The pathogenesis of liver cirrhosis involves a cascade of events initiated by chronic liver injury, which leads to the activation of hepatic stellate cells (HSCs). This activation is driven by pro-fibrotic signals, including transforming growth factor-beta (TGF-β) and the Wnt/β-catenin pathways. Recent studies have emphasized the importance of epigenetic regulation, mechanotransduction, and cellular crosstalk in perpetuating fibrogenesis [3]. As fibrosis progresses, it disrupts the liver's vascular architecture and impairs its ability to maintain homeostasis and immunological function [5].

Clinically, the assessment of liver cirrhosis involves evaluating various complications associated with portal hypertension, such as ascites, hepatic encephalopathy, and variceal bleeding. Each event of decompensation has prognostic implications, although predicting these events remains challenging [36]. Current diagnostic approaches for liver cirrhosis have evolved significantly, incorporating non-invasive tools that provide insights into liver fibrosis and function without the need for invasive liver biopsies. These include elastography and liquid biopsy technologies, which can assess circulating biomarkers such as extracellular vesicles and noncoding RNAs, offering real-time insights into disease dynamics [3].

The integration of non-invasive diagnostic modalities into clinical practice is essential for early detection and intervention in at-risk populations. Studies indicate that a significant percentage of individuals without known liver disease may have undetected liver fibrosis or established cirrhosis [37]. The implementation of serological tests and radiological methods has shown promise in accurately assessing liver fibrosis, potentially transforming the management of chronic liver diseases by shifting the focus from late-stage diagnosis to early intervention [37].

In summary, liver cirrhosis develops through a complex interplay of chronic liver injury, fibrogenesis, and systemic complications. The clinical assessment of cirrhosis is increasingly reliant on advanced non-invasive diagnostic approaches, enabling timely interventions that may alter the disease trajectory and improve patient outcomes [3][36][37].

5.2 Imaging Techniques ​

Liver cirrhosis is a complex and progressive condition that results from chronic liver injury, leading to extensive fibrosis, disruption of liver architecture, and impaired liver function. The development of cirrhosis is often a consequence of various chronic liver diseases, including viral hepatitis, alcoholic liver disease, and non-alcoholic fatty liver disease. The pathophysiology of cirrhosis involves a sustained inflammatory response that triggers the activation of hepatic stellate cells (HSCs), resulting in the accumulation of fibrous tissue. Key pro-fibrotic signals, such as transforming growth factor-beta (TGF-β) and the Wnt/β-catenin pathway, play crucial roles in this process [3].

As cirrhosis progresses, it leads to portal hypertension, liver cell failure, and increases the risk of developing hepatocellular carcinoma [38]. The disease often remains asymptomatic in its early stages, making early diagnosis challenging. Most patients are diagnosed at later stages when complications have already developed, underscoring the importance of effective screening and diagnostic approaches [39].

Diagnostic imaging techniques have evolved significantly to facilitate the assessment of liver fibrosis and cirrhosis. Traditional liver biopsy has been the gold standard for diagnosing liver fibrosis; however, it is invasive and carries risks of complications and sampling errors [40]. Consequently, there has been a shift towards non-invasive imaging techniques that provide reliable assessments of liver fibrosis.

Ultrasound (US) and its variants, including Doppler ultrasound and elastography, are widely used non-invasive tools. Ultrasound elastography, in particular, measures liver stiffness, which correlates with the degree of fibrosis. This technique is beneficial for diagnosing advanced liver cirrhosis, as it allows for the evaluation of liver stiffness without the need for invasive procedures [38].

Magnetic resonance imaging (MRI) and computed tomography (CT) have also emerged as advanced imaging modalities for assessing liver fibrosis. MRI techniques, such as MR elastography and diffusion-weighted imaging, offer enhanced diagnostic accuracy and can visualize liver tissue changes associated with fibrosis [40]. These imaging modalities can provide a comprehensive evaluation of liver structure and function, facilitating early diagnosis and management of cirrhosis.

In summary, liver cirrhosis develops as a result of chronic liver injury and inflammation, leading to significant fibrosis and functional impairment. Diagnostic approaches have evolved from invasive liver biopsies to non-invasive imaging techniques, including ultrasound elastography and advanced MRI, which significantly improve the ability to detect and monitor liver fibrosis and cirrhosis [3][41].

5.3 Biomarkers ​

Liver cirrhosis is a complex and progressive condition resulting from sustained liver injury and chronic inflammation, characterized by extensive fibrosis, disrupted liver architecture, and impaired function. The pathogenesis of liver cirrhosis involves several key processes, including the activation of hepatic stellate cells (HSCs) driven by pro-fibrotic signals such as transforming growth factor-beta (TGF-β) and Wnt/β-catenin pathways. Recent studies have underscored the significance of epigenetic regulation, mechanotransduction, and cellular crosstalk in perpetuating fibrogenesis. This progression is not only localized to the liver but also has systemic implications, impacting the gut-liver axis, vascular remodeling, and multi-organ dysfunction [3].

Diagnostic approaches for liver cirrhosis have evolved significantly, particularly with the introduction of non-invasive tools. These include elastography and liquid biopsy technologies, which allow for real-time insights into disease dynamics without the need for invasive liver biopsies. The advent of circulating biomarkers, such as extracellular vesicles and noncoding RNAs, has further enhanced diagnostic capabilities [3].

One notable biomarker associated with the progression of liver cirrhosis is CC motif chemokine ligand 16 (CCL16). Studies have shown that lower plasma levels of CCL16 correlate with elevated Child-Pugh scores and poorer prognoses in patients with chronic hepatitis B and liver cirrhosis. Specifically, plasma CCL16 levels were found to decrease in a stepwise pattern across healthy controls, chronic hepatitis B patients, and those with liver cirrhosis, indicating its potential as a non-invasive biomarker for predicting cirrhosis progression [42].

In addition to CCL16, other diagnostic advancements include the integration of artificial intelligence and machine learning techniques, which are anticipated to enhance predictive capabilities in cirrhosis management [41]. Moreover, prognostic scoring systems like the MELD and Child-Pugh are being refined with new biomarkers to improve risk stratification and clinical decision-making [41].

Overall, the understanding of liver cirrhosis development and progression, coupled with innovative diagnostic approaches and biomarkers, offers new avenues for intervention and management, aiming to bridge the gap between pathophysiology and effective therapeutic strategies [3][41][42].

6 Management and Treatment Strategies ​

6.1 Lifestyle Modifications ​

Liver cirrhosis is a complex and progressive condition resulting from sustained liver injury and chronic inflammation, characterized by extensive fibrosis, disrupted liver architecture, and impaired function. The pathogenesis of liver cirrhosis involves a cascade of events, including inflammation, necrosis, and the formation of fibrous tissue and regenerative nodules, ultimately leading to portal hypertension and liver dysfunction [1].

The development of cirrhosis is often driven by chronic liver diseases, with common etiologies including alcohol-associated liver disease (ALD), non-alcoholic fatty liver disease (NAFLD), and chronic viral hepatitis, particularly hepatitis C [16]. The progression of liver cirrhosis can be attributed to the activation of hepatic stellate cells (HSCs) by pro-fibrotic signals such as transforming growth factor-beta (TGF-β) and Wnt/β-catenin pathways [3]. Furthermore, dysbiosis of the gut microbiome has been implicated in the progression of liver diseases, as alterations in the microbiome can contribute to inflammation and disease exacerbation [6].

Management of liver cirrhosis is multifaceted, primarily focusing on the underlying causes and the prevention of disease progression. Lifestyle modifications play a crucial role in the management strategy. These modifications include:

  1. Alcohol Cessation: For patients with alcohol-related liver disease, complete abstinence from alcohol is essential to halt the progression of liver damage and improve liver function [43].

  2. Nutritional Interventions: Proper nutrition is vital for patients with liver cirrhosis. Dietary modifications may include a balanced diet rich in proteins, vitamins, and minerals, along with salt restriction to manage fluid retention and prevent complications such as ascites [4].

  3. Weight Management: For patients with NAFLD, achieving and maintaining a healthy weight through diet and exercise can significantly improve liver health and reduce the risk of progression to cirrhosis [3].

  4. Regular Monitoring and Medical Management: Regular follow-ups with healthcare providers are essential for monitoring liver function and managing complications. This includes screening for hepatocellular carcinoma and managing portal hypertension [16].

  5. Gut Microbiome Modulation: Interventions targeting the gut microbiome, such as probiotics and prebiotics, have shown promise in ameliorating liver disease and potentially reversing cirrhosis [44].

  6. Physical Activity: Encouraging regular physical activity can improve overall health and liver function, as it helps to maintain a healthy weight and reduces the risk of metabolic syndrome [1].

  7. Medication Compliance: Patients should adhere to prescribed medications that target the underlying causes of cirrhosis, such as antiviral agents for viral hepatitis or other specific treatments based on the etiology of liver disease [16].

In summary, the development and progression of liver cirrhosis are influenced by chronic liver injury, inflammation, and changes in the gut microbiome. Effective management strategies, particularly lifestyle modifications, are critical for slowing disease progression, improving patient outcomes, and enhancing quality of life.

6.2 Pharmacological Treatments ​

Liver cirrhosis is a complex and progressive condition resulting from sustained liver injury and chronic inflammation, characterized by extensive fibrosis, disrupted liver architecture, and impaired function. The pathogenesis of cirrhosis involves multiple mechanisms, including persistent inflammation, necrosis, and the formation of regenerative nodules, which ultimately lead to liver dysfunction and complications such as portal hypertension and hepatic encephalopathy [3].

The development of cirrhosis is often a consequence of various chronic liver diseases, including viral hepatitis, alcoholic liver disease, and non-alcoholic fatty liver disease. The liver responds to chronic injury by activating hepatic stellate cells (HSCs), which are key players in fibrogenesis, driven by pro-fibrotic signals such as transforming growth factor-beta (TGF-β) [3]. This fibrotic response can become maladaptive, leading to excessive extracellular matrix deposition and the eventual disruption of normal liver architecture.

Management of liver cirrhosis focuses on addressing the underlying causes, preventing disease progression, and treating complications. Pharmacological treatments have evolved, with several strategies being explored to manage cirrhosis effectively. These include antifibrotic agents, immunomodulators, and therapies targeting the gut-liver axis.

Antifibrotic therapies are crucial as fibrosis is a hallmark of cirrhosis and a key therapeutic target. Despite various antifibrotic strategies being developed, the results have often been unsatisfactory, indicating the need for further research into effective treatments [1]. Current pharmacological approaches include small molecular agents that aim to inhibit the pathways involved in fibrogenesis and promote liver regeneration [1].

Traditional Chinese medicine (TCM) has also shown promise in treating liver cirrhosis by regulating gut microbiota and restoring intestinal barrier function, which can ameliorate liver fibrosis and improve overall liver health [4]. TCM interventions, including herbal decoctions and acupuncture, have been noted for their efficacy in reversing cirrhosis and improving prognoses [45].

In addition to these pharmacological approaches, emerging strategies involve the use of stem cells, extracellular vesicles, and nanoparticles, which hold potential for targeted delivery of therapeutic agents and modulation of the liver microenvironment [1].

The role of the gut microbiome in liver cirrhosis is increasingly recognized, with dysbiosis contributing to liver inflammation and progression of the disease. Modulating the gut microbiota through probiotics or fecal microbiota transplantation (FMT) has been explored as a potential therapeutic strategy [3].

Overall, while liver transplantation remains the definitive treatment for end-stage cirrhosis, the exploration of innovative pharmacological interventions, combined with traditional and complementary therapies, represents a promising frontier in the management of liver cirrhosis. The integration of these diverse strategies may lead to improved patient outcomes and quality of life for those affected by this debilitating condition [16].

6.3 Liver Transplantation ​

Liver cirrhosis is a complex and progressive condition that arises from sustained liver injury and chronic inflammation, characterized by extensive fibrosis, disrupted liver architecture, and impaired function. It represents the end stage of various chronic liver diseases, with the activation of hepatic stellate cells (HSCs) being central to its development. This activation is driven by a cascade of pro-fibrotic signals, including transforming growth factor-beta (TGF-β) and Wnt/β-catenin pathways, leading to fibrogenesis. The disease progresses through stages of inflammation, necrosis, and regenerative nodule formation, ultimately resulting in significant vascular remodeling and portal hypertension, which can culminate in multi-organ dysfunction [1][3][16].

The progression of liver cirrhosis can be influenced by various factors, including the underlying etiology, such as chronic viral hepatitis (notably hepatitis C), alcoholic and non-alcoholic fatty liver disease, and autoimmune hepatitis. The complexity of cirrhosis is further compounded by its multifaceted complications, which include ascites, hepatic encephalopathy, variceal bleeding, and hepatocellular carcinoma. These complications severely compromise patient outcomes and quality of life [13][16].

Management strategies for liver cirrhosis are multifaceted, primarily focusing on the treatment of the underlying cause, management of complications, and improving patient quality of life. While liver transplantation is considered the definitive treatment for end-stage liver disease, its availability is limited by donor organ scarcity and contraindications. Therefore, alternative therapeutic strategies are being explored, including pharmacological interventions aimed at halting or potentially reversing disease progression [5][14].

Emerging treatment strategies involve targeting the gut-liver axis, which has been shown to play a significant role in cirrhosis progression. Dysbiosis in the gut microbiome has been implicated in the inflammatory processes associated with liver disease, and therapies such as probiotics and fecal microbiota transplantation (FMT) are being investigated for their potential to restore microbial balance and mitigate inflammation [6][44].

Recent advancements in diagnostic tools, such as elastography and liquid biopsy technologies, provide non-invasive methods to assess disease dynamics and monitor progression [3]. The use of circulating biomarkers, including extracellular vesicles and noncoding RNAs, is also gaining traction for real-time insights into liver disease [1].

In summary, the development and progression of liver cirrhosis involve a complex interplay of cellular and molecular mechanisms, with a significant focus on the inflammatory and fibrotic processes. Management strategies must be comprehensive, addressing both the underlying causes and the complications of the disease, with liver transplantation remaining the ultimate therapeutic option for eligible patients. Ongoing research is crucial to enhance treatment efficacy and improve patient outcomes in this challenging condition [1][3][16].

7 Conclusion ​

The findings presented in this review elucidate the multifaceted mechanisms underlying the development and progression of liver cirrhosis, emphasizing the critical roles of chronic inflammation, immune dysregulation, and the activation of hepatic stellate cells in fibrogenesis. The research highlights the importance of recognizing the stages of cirrhosis, from compensated to decompensated, and the associated clinical implications. Furthermore, it underscores the significance of identifying risk factors such as alcoholic liver disease, non-alcoholic fatty liver disease, and viral hepatitis, which contribute to the disease's progression. Current diagnostic approaches, including advanced imaging techniques and biomarkers, have shown promise in facilitating early detection and monitoring of cirrhosis. In terms of management, lifestyle modifications, pharmacological treatments, and innovative therapeutic strategies targeting the gut-liver axis are crucial for improving patient outcomes. Looking ahead, interdisciplinary research is essential to bridge the gap between pathophysiology and clinical practice, aiming to develop effective prevention and treatment strategies that can ultimately enhance the quality of life for patients suffering from liver cirrhosis.

References ​

  • [1] Zihe Dong;Yeying Wang;Weilin Jin. Liver cirrhosis: molecular mechanisms and therapeutic interventions.. MedComm(IF=10.7). 2024. PMID:39290252. DOI: 10.1002/mco2.721.
  • [2] Roman Maslennikov;Elena Poluektova;Oxana Zolnikova;Alla Sedova;Anastasia Kurbatova;Yulia Shulpekova;Natyia Dzhakhaya;Svetlana Kardasheva;Maria Nadinskaia;Elena Bueverova;Vladimir Nechaev;Anna Karchevskaya;Vladimir Ivashkin. Gut Microbiota and Bacterial Translocation in the Pathogenesis of Liver Fibrosis.. International journal of molecular sciences(IF=4.9). 2023. PMID:38003692. DOI: 10.3390/ijms242216502.
  • [3] Rabab Abdel-Majeed Hegazy. Unraveling Liver Cirrhosis: Bridging Pathophysiology to Innovative Therapeutics.. Journal of gastroenterology and hepatology(IF=3.4). 2025. PMID:40754005. DOI: 10.1111/jgh.70037.
  • [4] Siyuan Sun;Guangheng Zhang;Shimeng Lv;Jinhui Sun. Potential mechanisms of traditional Chinese medicine in the treatment of liver cirrhosis: a focus on gut microbiota.. Frontiers in microbiology(IF=4.5). 2024. PMID:39234554. DOI: 10.3389/fmicb.2024.1407991.
  • [5] Partha Pratim Das;Subhash Medhi. Role of inflammasomes and cytokines in immune dysfunction of liver cirrhosis.. Cytokine(IF=3.7). 2023. PMID:37639845. DOI: 10.1016/j.cyto.2023.156347.
  • [6] Rongrong Zhou;Xuegong Fan;Bernd Schnabl. Role of the intestinal microbiome in liver fibrosis development and new treatment strategies.. Translational research : the journal of laboratory and clinical medicine(IF=5.9). 2019. PMID:30853445. DOI: 10.1016/j.trsl.2019.02.005.
  • [7] Yu-Long Bao;Li Wang;Hai-Ting Pan;Tai-Ran Zhang;Ya-Hong Chen;Shan-Jing Xu;Xin-Li Mao;Shao-Wei Li. Animal and Organoid Models of Liver Fibrosis.. Frontiers in physiology(IF=3.4). 2021. PMID:34122138. DOI: 10.3389/fphys.2021.666138.
  • [8] Qiuyun Yi;Jinxian Yang;Ying Wu;Ying Wang;Qiqi Cao;Wen Wen. Immune microenvironment changes of liver cirrhosis: emerging role of mesenchymal stromal cells.. Frontiers in immunology(IF=5.9). 2023. PMID:37539053. DOI: 10.3389/fimmu.2023.1204524.
  • [9] Ye-Jiao Wu;Ming-Yi Xu;Lun-Gen Lu. Clinical Advances in Fibrosis Progression of Chronic Hepatitis B and C.. Journal of clinical and translational hepatology(IF=4.2). 2014. PMID:26357628. DOI: 10.14218/JCTH.2014.00029.
  • [10] Daniel Sepulveda-Crespo;Salvador Resino;Isidoro Martinez. Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis.. Drugs(IF=14.4). 2021. PMID:33400242. DOI: 10.1007/s40265-020-01458-x.
  • [11] Wen-Ce Zhou;Quan-Bao Zhang;Liang Qiao. Pathogenesis of liver cirrhosis.. World journal of gastroenterology(IF=5.4). 2014. PMID:24966602. DOI: 10.3748/wjg.v20.i23.7312.
  • [12] Han-Jing Zhangdi;Si-Biao Su;Fei Wang;Zi-Yu Liang;Yu-Dong Yan;Shan-Yu Qin;Hai-Xing Jiang. Crosstalk network among multiple inflammatory mediators in liver fibrosis.. World journal of gastroenterology(IF=5.4). 2019. PMID:31543677. DOI: 10.3748/wjg.v25.i33.4835.
  • [13] Paula Sánchez Sánchez;María Del Mar Rigual;Nabil Djouder. Inflammatory and Non-Inflammatory Mechanisms Controlling Cirrhosis Development.. Cancers(IF=4.4). 2021. PMID:34680192. DOI: 10.3390/cancers13205045.
  • [14] Sven Lamatsch;Richard Sittner;Frank Tacke;Cornelius Engelmann. Novel drug discovery strategies for the treatment of decompensated cirrhosis.. Expert opinion on drug discovery(IF=4.9). 2022. PMID:34971342. DOI: 10.1080/17460441.2022.2020755.
  • [15] Ruonan Xu;Zheng Zhang;Fu-Sheng Wang. Liver fibrosis: mechanisms of immune-mediated liver injury.. Cellular & molecular immunology(IF=19.8). 2012. PMID:22157623. DOI: 10.1038/cmi.2011.53.
  • [16] Hiba Fadlallah;Diala El Masri;Hisham F Bahmad;Wassim Abou-Kheir;Jad El Masri. Update on the Complications and Management of Liver Cirrhosis.. Medical sciences (Basel, Switzerland)(IF=4.4). 2025. PMID:39982238. DOI: 10.3390/medsci13010013.
  • [17] Thierry Gustot;Vanessa Stadlbauer;Wim Laleman;Carlo Alessandria;Mark Thursz. Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events.. Journal of hepatology(IF=33.0). 2021. PMID:34039491. DOI: 10.1016/j.jhep.2020.12.005.
  • [18] Dalila Costa;Jonel Trebicka;Cristina Ripoll;Richard Moreau;Rajiv Jalan;Thomas Reiberger. Interaction of inflammation and portal hypertension in cirrhosis progression.. Nature reviews. Gastroenterology & hepatology(IF=51.0). 2025. PMID:41023416. DOI: 10.1038/s41575-025-01107-2.
  • [19] Jonel Trebicka;Peer Bork;Aleksander Krag;Manimozhiyan Arumugam. Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure.. Nature reviews. Gastroenterology & hepatology(IF=51.0). 2021. PMID:33257833. DOI: 10.1038/s41575-020-00376-3.
  • [20] Cornelius Engelmann;Joan Clària;Gyongyi Szabo;Jaume Bosch;Mauro Bernardi. Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction.. Journal of hepatology(IF=33.0). 2021. PMID:34039492. DOI: 10.1016/j.jhep.2021.01.002.
  • [21] Ashwani K Singal;Philippe Mathurin. Diagnosis and Treatment of Alcohol-Associated Liver Disease: A Review.. JAMA(IF=55.0). 2021. PMID:34255003. DOI: 10.1001/jama.2021.7683.
  • [22] Mingyu Sun;Ziyi Yang;Fei Tang;Fenghui Li;Qing Ye;Chao Sun;Jing Liang. Alcoholic cirrhosis-associated immune dysfunction: What does it imply for us?. Annals of hepatology(IF=4.4). 2025. PMID:40379022. DOI: 10.1016/j.aohep.2025.101927.
  • [23] Marsha Y Morgan;Moksh Sharma;Stephen R Atkinson. Genetic and Environmental Susceptibility to Alcoholic Hepatitis.. Clinics in liver disease(IF=4.1). 2021. PMID:34229837. DOI: 10.1016/j.cld.2021.04.001.
  • [24] Irene Pierantonelli;Gianluca Svegliati-Baroni. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.. Transplantation(IF=5.0). 2019. PMID:30300287. DOI: 10.1097/TP.0000000000002480.
  • [25] Ahmed M Samy;Mohamed A Kandeil;Dina Sabry;A A Abdel-Ghany;Mohamed O Mahmoud. From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences.. Heliyon(IF=3.6). 2024. PMID:38737288. DOI: 10.1016/j.heliyon.2024.e30387.
  • [26] Santosh Kumar;Qihua Duan;Rongxue Wu;Edward N Harris;Qiaozhu Su. Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis.. Advanced drug delivery reviews(IF=17.6). 2021. PMID:34280515. DOI: 10.1016/j.addr.2021.113869.
  • [27] Liangliang Zhou;Haiyuan Shen;Xiaofeng Li;Hua Wang. Endoplasmic reticulum stress in innate immune cells - a significant contribution to non-alcoholic fatty liver disease.. Frontiers in immunology(IF=5.9). 2022. PMID:35958574. DOI: 10.3389/fimmu.2022.951406.
  • [28] Amina Basha;Sarah C May;Ryan M Anderson;Niharika Samala;Raghavendra G Mirmira. Non-Alcoholic Fatty Liver Disease: Translating Disease Mechanisms into Therapeutics Using Animal Models.. International journal of molecular sciences(IF=4.9). 2023. PMID:37373143. DOI: 10.3390/ijms24129996.
  • [29] Scott L Friedman;Brent A Neuschwander-Tetri;Mary Rinella;Arun J Sanyal. Mechanisms of NAFLD development and therapeutic strategies.. Nature medicine(IF=50.0). 2018. PMID:29967350. DOI: 10.1038/s41591-018-0104-9.
  • [30] Duarte M S Ferreira;André L Simão;Cecília M P Rodrigues;Rui E Castro. Revisiting the metabolic syndrome and paving the way for microRNAs in non-alcoholic fatty liver disease.. The FEBS journal(IF=4.2). 2014. PMID:24702768. DOI: 10.1111/febs.12806.
  • [31] Ángela Rojas;María Rosario García-Lozano;Antonio Gil-Gómez;Manuel Romero-Gómez;Javier Ampuero. Glutaminolysis-ammonia-urea Cycle Axis, Non-alcoholic Fatty Liver Disease Progression and Development of Novel Therapies.. Journal of clinical and translational hepatology(IF=4.2). 2022. PMID:35528989. DOI: 10.14218/JCTH.2021.00247.
  • [32] Alessandro Ciavarella;Davide Gnocchi;Carlo Custodero;Gennaro Mariano Lenato;Giorgio Fiore;Carlo Sabbà;Antonio Mazzocca. Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease.. Thrombosis research(IF=3.4). 2021. PMID:33340925. DOI: 10.1016/j.thromres.2020.12.002.
  • [33] Ji Lin;Jian-Feng Wu;Qi Zhang;Hong-Wei Zhang;Guang-Wen Cao. Virus-related liver cirrhosis: molecular basis and therapeutic options.. World journal of gastroenterology(IF=5.4). 2014. PMID:24914367. DOI: 10.3748/wjg.v20.i21.6457.
  • [34] Bushra Ijaz;Waqar Ahmad;Trina Das;Khadija Shabbiri;Tayyab Husnain;Sajida Hassan. HCV infection causes cirrhosis in human by step-wise regulation of host genes involved in cellular functioning and defense during fibrosis: Identification of bio-markers.. Genes & diseases(IF=9.4). 2019. PMID:32042870. DOI: 10.1016/j.gendis.2019.04.007.
  • [35] María Martínez-Esparza;María Tristán-Manzano;Antonio J Ruiz-Alcaraz;Pilar García-Peñarrubia. Inflammatory status in human hepatic cirrhosis.. World journal of gastroenterology(IF=5.4). 2015. PMID:26556984. DOI: 10.3748/wjg.v21.i41.11522.
  • [36] James Maurice;Massimo Pinzani. The stratification of cirrhosis.. Hepatology research : the official journal of the Japan Society of Hepatology(IF=3.4). 2020. PMID:32072721. DOI: 10.1111/hepr.13493.
  • [37] Pere Ginès;Laurent Castera;Frank Lammert;Isabel Graupera;Miquel Serra-Burriel;Alina M Allen;Vincent Wai-Sun Wong;Phillipp Hartmann;Maja Thiele;Llorenç Caballeria;Robert J de Knegt;Ivica Grgurevic;Salvador Augustin;Emmanuel A Tsochatzis;Jörn M Schattenberg;Indra Neil Guha;Andrea Martini;Rosa M Morillas;Montserrat Garcia-Retortillo;Harry J de Koning;Núria Fabrellas;Judit Pich;Ann T Ma;M Alba Diaz;Dominique Roulot;Philip N Newsome;Michael Manns;Patrick S Kamath;Aleksander Krag; . Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases.. Hepatology (Baltimore, Md.)(IF=15.8). 2022. PMID:34537988. DOI: 10.1002/hep.32163.
  • [38] Maurizio Soresi;Lydia Giannitrapani;Melchiorre Cervello;Anna Licata;Giuseppe Montalto. Non invasive tools for the diagnosis of liver cirrhosis.. World journal of gastroenterology(IF=5.4). 2014. PMID:25561782. DOI: 10.3748/wjg.v20.i48.18131.
  • [39] Pere Ginès;Isabel Graupera;Frank Lammert;Paolo Angeli;Llorenç Caballeria;Aleksander Krag;I Neil Guha;S Darwish Murad;Laurent Castera. Screening for liver fibrosis in the general population: a call for action.. The lancet. Gastroenterology & hepatology(IF=38.6). 2016. PMID:28404098. DOI: 10.1016/S2468-1253(16)30081-4.
  • [40] Silvana C Faria;Karthik Ganesan;Irene Mwangi;Masoud Shiehmorteza;Barbara Viamonte;Sameer Mazhar;Michael Peterson;Yuko Kono;Cynthia Santillan;Giovanna Casola;Claude B Sirlin. MR imaging of liver fibrosis: current state of the art.. Radiographics : a review publication of the Radiological Society of North America, Inc(IF=5.5). 2009. PMID:19959511. DOI: 10.1148/rg.296095512.
  • [41] Ashok Kumar Sah;Mohd Afzal;Rabab H Elshaikh;Anass M Abbas;Manar G Shalabi;Pranav Kumar Prabhakar;Asaad M A Babker;Fariza Tursunbaevna Khalimova;Velilyaeva Aliya Sabrievna;Ranjay Kumar Choudhary. Innovative Strategies in the Diagnosis and Treatment of Liver Cirrhosis and Associated Syndromes.. Life (Basel, Switzerland)(IF=3.4). 2025. PMID:40430206. DOI: 10.3390/life15050779.
  • [42] Jian-Yong Zhuo;Di Lu;Zu-Yuan Lin;Bei-Ni Cen;Xu-Yong Wei;Hai-Yang Xie;Shu-Sen Zheng;Xiao Xu. CC motif chemokine ligand 16 inhibits the progression of liver cirrhosis via inactivating hepatic stellate cells.. Hepatobiliary & pancreatic diseases international : HBPD INT(IF=4.4). 2020. PMID:31948840. DOI: 10.1016/j.hbpd.2019.12.006.
  • [43] Madhumita Premkumar;Anil C Anand. Overview of Complications in Cirrhosis.. Journal of clinical and experimental hepatology(IF=3.2). 2022. PMID:35814522. DOI: 10.1016/j.jceh.2022.04.021.
  • [44] Na Young Lee;Ki Tae Suk. The Role of the Gut Microbiome in Liver Cirrhosis Treatment.. International journal of molecular sciences(IF=4.9). 2020. PMID:33379148. DOI: 10.3390/ijms22010199.
  • [45] Shihao Zheng;Chengyuan Xue;Size Li;Xiaobin Zao;Xiaoke Li;Qiyao Liu;Xu Cao;Wei Wang;Wenying Qi;Hongbo Du;Peng Zhang;Yongan Ye. Liver cirrhosis: current status and treatment options using western or traditional Chinese medicine.. Frontiers in pharmacology(IF=4.8). 2024. PMID:39081955. DOI: 10.3389/fphar.2024.1381476.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Liver Cirrhosis · Chronic Liver Injury · Inflammation and Fibrosis · Risk Factors · Therapeutic Strategies

© 2025 MaltSci